Skip to NavigationSkip to content

Rozlytrek

Roche secures world first with Japanese Rozlytrek approval in advanced recurrent solid tumours

Roche’s personalised cancer therapy Rozlytrek (entrectinib) has seen its first approval: the drug has been approved in Japan for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced recurrent solid tumours in both adult and paediatric patients, it has emerged.

As well as representing Rozlytrek’s first approval worldwide, the decision also marks the first authorisation of a tumour-agnostic medicine in Japan that targets NTRK gene fusions, which have implications in the treatment of a range of solid tumour types including pancreatic, breast, lung, c

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches